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OBJECTIVES: Condoliase, an enzyme that specifically degrades glycosaminogly-
cans, main constituents of the nucleus pulposus, and reduces the compressions on 
nerves, can serve as a less-invasive curative treatment for patients with lumbar disc 
herniation and is expected to reduce associated medical cost due to shortened hos-
pital stays. This study aims to evaluate the cost-effectiveness of the treatment with 
condoliase compared with conventional surgical therapy in the Japanese healthcare 
system. METHODS: A Markov model was developed to estimate quality-adjusted 
life year (QALY) and associated costs over 1 year. QOL scores were converted from 
corresponding Oswestry Disability Index (ODI). ODI of condoliase group came from 
the results of a phase 3, multicenter, double-blind, randomized placebo-controlled 
study conducted in Japan. ODI of surgery group was estimated from the values 
obtained from published literatures. The risk of re-operation after treatment was 
considered during calculation. Surgical treatment costs and re-operation costs were 
collected and estimated using a Japanese administrative claims database (Japan 
Medical Data Center, JMDC). Payer perspective was adopted, and discounting was 
not applied due to the short timeframe of the analysis. One-way sensitivity analysis 
was performed to assess the impact of parameter uncertainty on the model’s con-
clusion. RESULTS: Average cost and effectiveness gained per patient for condoliase 
group and surgery group were 385,344 JPY vs. 798,919 JPY, 0.694 QALY vs. 0.685 QALY, 
respectively, meaning condoliase group was dominant compared to surgery group. 
One-way sensitivity analysis showed the robustness of this result. CONCLUSIONS: 
From the payer perspective, treatment with condoliase for patients with lumbar disc 
herniation in Japan is expected to reduce medical costs compared to conventional 
surgery treatment even taking into account the uncertainties.
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OBJECTIVES: Rheumatoid Arthritis (RA) destroys synovial joints and generates 
pain. Its prevalence in Chile has been estimated to be 0.46% (IC 95% 0.24-0.8). 
Available drugs for treatment include conventional synthetic Disease-Modifying 
Antirheumatic Drugs (csDMARDs), biological therapies and a new drug approved for 
treatment after failure of csDMARDs: tofacitinib. The aim of this study is to compare 
the costs-effectiveness of tofacitinib relative to biological therapies as an initial 
treatment in adults with RA after failure of methotrexate in Chile. METHODS: A 
simulation model of individual patients compared two treatment sequences for RA: 
tofacitinib vs biological therapy as initial medications; always assuming a combina-
tion therapy with methotrexate; biological therapies validated with rheumatologists 
and included in the model were etanercept, infliximab, tocilizumab, adalimumab, 
rituximab and salvage therapy (defined by experts). The characteristics of the 
patient included: age, weight, initial HAQ score, and clinical response to short and 
long term treatment. HAQ scores were used to calculate utilities, measured in QALYs 
based on literature information. All costs were obtained from public tenders and 
official reports from Chilean Ministry of Health. The analysis was made from third 
payer perspective with one, five, ten years and lifetime horizon. Annual discount 
rate was 3% for costs and outcomes. Results are expressed in USD2014 (US$1 = 
CLP$600) RESULTS: Total costs, for year one of treatment was US$9,627 starting the 
sequence with tofacitinib and US$11,638 starting with etanercept; obtained HAQ-
QALYs were 0.76 and 0.68, respectively. The total cost of the sequence strategy for 
lifetime horizon initiating with tofacitinib, was US$236,373 compared to the treat-
ment with biological therapy: US$259,403 with a difference of 0.62HAQ-QALY for 
utility. The costs included the drug, administration and health care. CONCLUSIONS: 
The sequence of treatment initiating with tofacitinib for RA Arthritis is a dominant 
strategy compared to biological therapies used in Chile. Net savings with this drug 
is US$35,006
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OBJECTIVES: Primary Total Hip Arthroplasty(THA) provides quality of life to 
patients and is cost-effective. Improvements to implant life have focused on the 
bearing surface with ceramic-on-polyethylene (CoP) bearing use growing rapidly 
due to evidence of longer implant life. We sought to determine if the increased 
CoP cost over the metal-on-polyethylene (MoP) provides enough benefit through 
lower revision rate to justify its utilization. METHODS: A Markov decision model 
was designed to determine the reduction in CoP 20-year revision rate required 
to make this implant cost-effective compared to MoP. Premier’s 2012 Research 
Database provided hospitalization costs for primary and revision surgeries. The 
Orthopedic Research Network (ORN) provided aggregated implant purchase price 
information. The HealthEast Joint Registry was the source of the MoP revision rate 
used for comparison. At each 10-year age increment/bearing cost condition, the 
CoP revision rate was varied until the lifetime costs were equal for the 2 different 
bearings. RESULTS: The sample included 20,398 patients aged 45-89+ from 475 US 
hospitals with identified bearing surfaces. CoP vs. MoP surface cost differences were 
$325+/-$177(p= 0.014) and $1,003+/-$710(p= 0.003), respectively, based on unadjusted 
and adjusted analysis of Premier data. ORN reports indicated a $600 difference 
in 2012. Revision costs were $23,628+/-$385 on 8,566 patients. HealthEast’s data 
indicates a 20-year MoP revision rate of 14.5/100THAs. An inflection in the revision 
scores (and changes) using results of a mixed treatment comparison (first 6 months) 
and data from long-term extension trials (later treatment periods). Where available, 
meta-analysis data were used to estimate adverse events incidence, followed by 
individual trial data and registry estimates. Canadian data from published sources 
were used to derive healthcare resource utilization costs and EuroQol-5D scores 
from HAQ-DI scores. All costs were estimated in 2014 Canadian dollars. Probabilistic 
and one-way sensitivity analyses were completed on analytical horizon, event rates, 
and efficacy thresholds. RESULTS: After running the model for 100,000 simula-
tions of moderate to severe RA patients, the treatment arm including tofacitinib 
had lifetime costs of $298,434 with 8.17 QALYs. Comparatively, the treatment arm 
excluding tofacitinib had a lifetime cost of $305,158 with 7.88 QALYs. Therefore, a 
treatment strategy including tofacitinib is dominant with lower costs and greater 
effectiveness. One-way and probabilistic sensitivity analysis reflected the robust-
ness of these results. CONCLUSIONS: The inclusion of tofacitinib into the treatment 
strategy for moderate to severe RA is a dominant strategy in Canada (lower cost 
and increased QALYs).
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory condition with 
significant economic burden. Tofacitinib is an oral Janus kinase inhibitor indicated 
in the US for the treatment of moderate to severe RA in patients with inadequate 
response to methotrexate. Given the similarity of indications across available 
therapies, economic evaluation of alternate treatment strategies could inform 
US formulary decisions. We estimated incremental cost-effectiveness ratios of 
tofacitinib after methotrexate failure in a treatment sequence compared with 
a similar sequence without tofacitinib from a US third-party payer’s perspec-
tive. METHODS: The model estimated costs and outcomes of RA treatment 
with a pre-specified “treatment sequence” (sequential methotrexate, tofacitinib, 
adalimumab, abatacept, tocilizumab, rituximab) versus a “comparator sequence” 
(sequential methotrexate, etanercept, adalimumab, abatacept, tocilizumab, rituxi-
mab). Alternative sequences were considered. Efficacy was assessed by Health 
Assessment Questionnaire (HAQ) and compared using mixed treatment com-
parison and data from long-term extension trials. Adverse event data were from 
published meta-analyses and trials of tofacitinib and comparators. Patient char-
acteristics were based on tofacitinib clinical trials (NCT00856544; NCT00847613; 
NCT00853385). RA-related costs were from published data mapping HAQ onto 
healthcare resource utilization in US patients with RA. Indirect costs were not con-
sidered. RESULTS: From a US third-party payer’s perspective, the predicted lifetime 
cost of “treatment sequence” including tofacitinib was $509,047 versus $546,860 for 
“comparator sequence” without tofacitinib, with the difference primarily driven by 
drug cost. The “treatment sequence” with tofacitinib resulted in an additional 0.11 
quality-adjusted life years versus “comparator sequence.” Probabilistic sensitivity 
analysis suggested the probability that tofacitinib is cost-effective as second-line 
therapy is 64.0% at a threshold of $100,000. CONCLUSIONS: Our model suggests 
that including tofacitinib as second-line therapy following methotrexate failure 
is a cost-effective alternative versus a “comparator sequence” without tofacitinib. 
Sensitivity analysis reiterated robustness of the findings and cost-effectiveness 
of including tofacitinib. Results of alternate treatment sequence comparisons 
were similar.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the 
musculoskeletal system. After inadequate response (IR) to anti-tumor necrosis fac-
tor (anti-TNF) treatments, the clinical and economic value of alternative biologic 
agents is unclear. We sought to estimate the cost-effectiveness of tocilizumab 
versus abatacept from a U.S. payer perspective. METHODS: We constructed a 
treatment-regimen based cohort model with a lifetime horizon. The model evalu-
ated the treatment comparison of tocilizumab (162mg every other week with 
escalation to weekly for inadequate responders) vs. abatacept (125mg, weekly). In 
this comparison, treatment initiation was followed by a certolizumab-tofacitinib-
rituximab-palliative care sequence. Treatment response rates were applied every 
6 months. Health related quality of life was mapped to the health assessment 
questionnaire (HAQ) for RA. Mortality was modelled allowing for both non-RA and 
RA-specific mortality predicted by the HAQ. Costs were derived from published 
sources and included drug treatment, monitoring, and direct medical resource 
utilization. Costs and QALYs were discounted at 3%. Sensitivity analyses were 
performed to test the robustness of the model results. RESULTS: Comparing the 
two initial treatments, tocilizumab dominated abatacept yielding better outcomes 
and fewer costs. Probabilistic sensitivity analyses indicated substantial uncer-
tainty, yet the mean estimates remained consistent with the deterministic results. 
Tociluzumab had an 89% probability of being cost-effective at $50,000/QALY. The 
one-way sensitivity analysis indicated that the parameters related to baseline 
HAQ and improvement in the ACR 50 and 70 rates had the most impact on model 
results. CONCLUSIONS: Management of TNF-IR patients with RA represents a 
challenge for the health care system. Compared to abatacept, tocilizumab appears 
to represent a lower cost treatment option with improved outcomes. However, 
with the attendant uncertainty, head-to-head trials of these agents may be 
warranted.
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treatments only, in the patient care pathway. The sequence of biologics treatments 
used in both cases is: Infliximab, Adalimumab, Tocilizumab, Rituximab, Etanercept 
and salvage therapy, according to experts opinion from MINSA [2]. All patients 
received concomitant treatment with methotrexate. The characteristics included 
in model are: age, weight, initial HAQ score, severe adverse events (SAE) and clini-
cal response to short and long term treatment; randomized controlled trials were 
used as source information when local information was not available [3,4]. HAQ 
scores were used to calculate utilities, measured in QALYs [5,6,7]. Only direct costs 
were considerate from MINSA databases of 2014 [8]. A lifetime horizon time was 
used with an annual discount rate of 5%. RESULTS: Total cost and total QALY per 
patient in a lifetime period are $193,971 and 9.28 QALY for treatment sequence 
with Tofacitinib; $205,015 and 9.20 for treatment sequence with biologic therapy. 
The cost saving for treatment sequence with Tofacitinib in years one, five and ten 
were: 12%, 10%, 8% respectively. CONCLUSIONS: In case of MINSA, the sequence 
initiating with Tofacitinib is a cost-saving alternative compared with biologic 
therapy.
PMS55
EConoMiC EvAluAtion of tiMEly vErSuS dElAyEd uSE of Anti-tuMor 
nECroSiS fACtor (tnf) biologiCS in thE trEAtMEnt of PSoriAtiC 
ArthritiS (PSA) in thE uS
Zhou Z.1, Signorovitch J.E.2, Griffith J.M.3, Zhong Y.1, Ganguli A.3
1Analysis Group Inc., Boston, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Abbvie Inc., 
North Chicago, IL, USA
OBJECTIVES: Progression of PsA can lead to irreversible damage, functional impair-
ment, and associated healthcare costs. Anti-TNF biologics have been shown to delay 
PsA progression and seem to have better efficacy compared with apremilast, a phos-
phodiesterase-4 inhibitor recently approved for PsA. The impact of using apremilast 
prior to anti-TNF has not been fully understood. This study evaluated the economic 
impacts of timely versus delayed use of anti-TNF among patients with moderately-
to-severely active PsA from a US payer perspective. METHODS: A Markov model 
was developed to evaluate the costs and outcomes of two treatment sequences over 
a one-year time horizon. PsA patients received either adalimumab (timely use of 
anti-TNF) or apremilast (delayed use) as initial treatment. Those who did not achieve 
ACR20 response in the first 12 weeks of treatment or who lost ACR20 response 
would use subsequent treatments, which included a mixture of anti-TNF biologics, 
followed by palliative care. Efficacy was based on ACR20 response, changes in the 
Health Assessment Questionnaire (HAQ), and reduction in skin lesions measured 
by the Psoriasis Area and Severity Index (PASI). Direct costs, including treatment-
related costs and other medical costs, and incremental costs per responder were 
calculated. Subgroup analyses among patients with moderate-to-severe psoriasis 
were performed. RESULTS: After one year, patients starting with adalimumab had 
higher ACR20 response rates and higher costs than apremilast (70.4% vs. 59.6%, 
$37,732 vs. $31,173). The one-year incremental cost per ACR20 responder was 
$60,766 for timely vs. delayed use of anti-TNF. Among the subgroup with psoriasis, 
starting with adalimumab lead to higher response rates in both ACR20 and PASI75 
and higher costs compared with apremilast (43.2% vs. 30.0%, $39,329 vs. $33,143). 
The incremental cost per ACR20+PASI75 responder was $46,949. CONCLUSIONS: 
Timely use of anti-TNF is a cost-effective strategy for the management of PsA due 
to improvements in joint and skin condition.
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OBJECTIVES: This study aims to perform a cost-effectiveness analysis of biologic 
alternatives for rheumatoid arthritis (RA), psoriasis (PSO) and ankylosing spon-
dylitis (AS) in Brazil, from public and private perspectives. METHODS: A deci-
sion tree model was developed for AR and PSO to evaluate the cost-effectiveness 
of biological drugs (etanercept, adalimumab, infliximab, tocilizumab, abatacept 
and rituximab). Effectiveness measures were extracted from literature and out-
comes included: ACR20 and ACR70 responses, and HQA for RA; and PASI 75 suc-
cess rate for PSO. Only costs were compared for AS because the model assumed 
the same effectiveness for drugs, according to literature review. Direct medical 
costs included biological acquisition, adverse events management and infusion 
(if applicable), presented in 2014 BRL. RESULTS: From the public perspective, in 
AR, etanercept was the most cost-effective option when compared to others drugs 
for all measures (158,731 BRL for ACR20, 282,448 BRL for ACR70 and 121,946 BRL for 
HAQ), followed by adalimumab, infliximab and tocilizumab, and rituximab. The 
same result was observed for PSO. Etanercept showed a cost-effectiveness ratio 
per PASI 75 response of 104,820 BRL versus 110,886 BRL for adalimumab. From the 
private perspective, once again etanercept was the most cost-effective option 
for all evaluated diseases. In RA, the cost-effectiveness ratios per ACR20, ACR70 
and HAQ were 193,211 BRL, 343,802 BRL, 148,435 BRL, respectively, and in PSO the 
value observed per PASI 75 response was 133,871 BRL versus 179,607 BRL for adali-
mumab and 268,504 BRL for infliximab. In AS, from both perspectives, etanercept 
represented the least costly option: 55,581 BRL versus 69,602 BRL for infliximab 
(public); 70,985 BRL versus 75,435 BRL for adalimumab and 99,883 BRL for inflixi-
mab (private). CONCLUSIONS: Etanercept showed the best cost-effectiveness ratio 
and lower costs when compared to others biological drugs in the management of 
AR, PSO and AS, from both Brazilian perspectives.
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rate-cost-age curve at 70yo prompted further consideration. Markov analysis indi-
cated the cost-effective CoP revision rate to be 12.5 revisions/100THAs at $325 cost 
difference and 9.0/100THAs at $1,003 cost difference, in a 70yo patient, indicating 
that CoP can be cost-effective. CONCLUSIONS: Shifting from MoP to CoP can be 
justified depending on the patient age, cost of the device, and actual CoP revision 
rate. All else equal, shifting all THAs in patients below age 70 to CoP and over 70 to 
MoP can be cost justified, even in the highest cost difference case.
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OBJECTIVES: Etanercept (ETA), certolizumab (CZP) and golimumab (GLM), each 
in combination with methotrexate (MTX) are the currently indicated treatment 
regimen for moderate to severe rheumatoid arthritis (RA). Recently, a novel oral 
agent, tofacitinib (CP-690550), was approved to treat RA. This study assesses the 
relative costs and effectiveness of these four disease modifying antirheumatic drugs 
(DMARDs) from a societal perspective. METHODS: We developed a Markov model 
that tracked a cohort of patients through the four disease states of RA progression, 
defined based on the patients’ disease activity score (DAS28). We estimated each 
drug’s effectiveness from published head-to-head clinical trial data. We derived 
quality of life utility scores and costs data for each disease state from the published 
literature. For each agent, we estimated the discounted costs, quality-adjusted life 
years (QALYs) and incremental cost-effectiveness ratios (ICERs). Univariate sensi-
tivity analyses were conducted to assess the impact of parameter uncertainty on 
our results. RESULTS: Relative to other drugs, and at the average US societal will-
ingness to pay (WTP) threshold of $150,000/QALY gained, ETA+MTX was the most 
cost-effective treatment regimen, with an ICER of $US 15,670/QALY gained when 
compared with CZP+MTX. The novel oral agent, CP-690550, was also relatively cost-
effective, with an ICER of $US 31,643/QALY gained relative to CZP+MTX. GLM+MTX 
was not deemed cost-effective ($239,000/QALY gained) relative to all other regimens, 
at the conventional US WTP threshold. Sensitivity analyses showed that results were 
very sensitive to the costs of each treatment. CONCLUSIONS: ETA+MTX is the most 
cost-effective treatment for moderate to severe RA in US patients. Compared to 
CZP+MTX, the novel oral agent, CP-690550, is also highly cost-effective. GLM+MTX 
is not cost-effective.
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OBJECTIVES: To compare health outcomes and costs associated with a treatment 
sequence that includes tofacitinib with another treatment sequence without tofaci-
tinib in patients with Rheumatoid Arthritis (RA) who failed to DMARDS from the 
payer’s perspective of the Ministry of public healthcare in Ecuador. METHODS: We 
compared with an Excel-based patient level simulation model, in a lifetime horizon, 
two treatment sequences, 1) treatment sequence: includes the use of tofacitinib, 
etanercept, adalimumab, tocilizumab, rituximab and salvage therapy, 2) compara-
tor sequence: includes the use of adalimumab, etanercept, inflximab, tocilizumab, 
rituximab and salvage therapy. All patients modeled received concomitant treat-
ment with methotrexate. Based on the available randomized controlled trials, HAQ 
score and clinical response to short and long term treatment data were obtained to 
calculate utilities, which were measured in QALYs. All costs information 2014 (drug 
and adverse events) were obtained from public data sources of the Ministry of Public 
Healthcare in Ecuador. RESULTS: Total costs in the lifetime horizon of treatment 
were $199,707.58 USD for the treatment sequence and $213,956.21 USD in the com-
parator sequence. Incremental costs for drug costs, administration costs, healthcare 
resources costs and other costs in the treatment sequence were -$11,881.02 USD, 
-$213.48 USD, -$460.56 USD and -1,694.60 USD respectively compared with the com-
parator sequence. Also the treatment sequence showed an incremental QALYs gain 
of 0.26 compared with the comparator sequence. CONCLUSIONS: Results suggest 
that the sequence treatment that includes the use of tofacitinib, represent a cost-
saving alternative when compared to the comparator sequence, in patients with 
Rheumatoid Arthritis (RA) who failed to DMARDS. This may represent savings for 
the Ministry of Public Healthcare in Ecuador.
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BACKGROUND: Rheumatoid Arthritis (RA) affects approximately 0.4% of the 
Latin American population over 16 years old. [1]. Many patients with rheumatoid 
arthritis (RA) do not respond adequately with disease-modifying antirheumatic 
drugs (DMARDs), being eligible for biological treatment available. OBJECTIVES: 
The objective was to evaluate the cost-effectiveness of Tofacitinib as second line 
vs continue using biological therapies in moderate RA after failure of DMARDs 
in Panama’s Ministry of Health (MINSA) in 2014. METHODS: The cost-effective-
ness model uses a patient-level simulation approach and assesses the economic 
and health benefits for the management of patients with RA who have an inad-
equate response to methotrexate. The model compares a treatment sequence 
with Tofacitinib followed by biologic treatments vs a sequence of biological 
